- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
India renew Engagement Strategy with CEPI for cooperation on vaccine, allied technology RnD

New Delhi: The Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, along with its Public Sector Undertaking, Biotechnology Industry Research Assistance Council (BIRAC) have signed the ‘Engagement Strategy’ with Coalition for Epidemic Preparedness Innovations (CEPI) on 18th September, 2025 for cooperation on vaccine and allied technology research, development and innovation.
This is a renewal of the earlier Engagement Strategy which was executed in October 2019 for a period of five years. The matter has been considered and noted by the Union Cabinet.
CEPI is a partnership between public, private, philanthropic and civil organisations to stimulate and accelerate the development of vaccines and associated competencies/technologies against emerging infectious diseases and enable access to people during outbreaks. As of March 2025, several national governments, the European Commission and philanthropic organisations, such as Gates Foundation and Welcome Trust are involved with CEPI.
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential. Key achievements of this cooperation include early-stage development of vaccine candidates for Chikungunya, Coronavirus and Monkey pox; creation of shared infrastructure such as bioassay laboratory and animal facility; and conducting capacity building/training programmes. The DBT-BRIC-THSTI bioassay laboratory and the experimental animal facility have been recognized by the global CEPI as part of their Centralized Lab Network Lab and CEPI Animal Lab Network, respectively. These facilities serve as national resources for vaccine development. The Bioassay lab has so far supported development of several Indian and global vaccine candidates at different stages, from pre-clinical to phase-3 efficacy trials. In addition, training programmes on vaccine development and clinical trials have been organized, contributing to capacity building in the domain.
Taking note of these achievements and also to continue this engagement further for cooperation on vaccine and allied technology research, development and innovation, the ‘Engagement Strategy’ between DBT, BIRAC and CEPI has been renewed. The scope of the renewed Engagement Strategy has been broadened to encompass research and development for allied technologies, such as monoclonal antibodies. The pathogens addressed by CEPI will include those identified in the WHO Blueprint list of priority diseases.
Renewal of the ‘Engagement Strategy’ with global CEPI is a significant step in advancing India’s R&D preparedness to pandemics, leveraging CEPI’s technical expertise and strong R&D capabilities. By fostering collaboration and by strengthening critical infrastructure & skilled human resources, this engagement aims to enable timely and effective response to emerging health threats, contributing to the broader goals of good health and well-being, aligning with national development priorities and Sustainable Development Goals.
Read also: Modified mRNA Flu Vaccine Shows Superior Protection in Major Global Trial
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

